Basics Madrigal Pharmaceuticals, Inc. Madrigal Pharmaceuticals Inc is a company focused on the development of novel compounds for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). IPO Date: February 6, 2007 Sector: Healthcare Industry: Biotech Market Cap: $6.05B Activated in VL: True Average Daily Range Avg Daily Range: $3.54 | 2.60% Avg Daily Range (30 D): $5.74 | 1.92% Avg Daily Range (90 D): $7.56 | 2.36% Institutional Daily Volume Avg Daily Volume: .21M Avg Daily Volume (30 D): .27M Avg Daily Volume (90 D): .28M Trade Size Avg Trade Size (Sh.): 45 Avg Trade Size (Sh.) (30 D): 31 Avg Trade Size (Sh.) (90 D): 31 Institutional Trades Total Inst.Trades: 2,215 Avg Inst. Trade: $5.64M Avg Inst. Trade (30 D): $9M Avg Inst. Trade (90 D): $13.33M Avg Inst. Trade Volume: .03M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $5.92M Avg Closing Trade (30 D): $10.05M Avg Closing Trade (90 D): $13.43M Avg Closing Volume: 32.13K     News May 10, 2025 @ 11:15 AM Madrigal Announces New Clinical Data Demonstrating... Source: N/A Apr 18, 2025 @ 12:00 PM Madrigal Pharmaceuticals to Release First-Quarter ... Source: N/A Feb 26, 2025 @ 5:28 PM Madrigal Pharmaceuticals Stock Jumps On New Two-Ye... Source: Vandana Singh Feb 26, 2025 @ 4:27 PM Why Madrigal Pharmaceuticals Stock Is Soaring Toda... Source: Keith Speights Feb 12, 2025 @ 1:00 PM Madrigal Pharmaceuticals to Release Fourth-Quarter... Source: N/A Financials   TTM Q1 2025 Q4 2024 Basic EPS $-17.93 $-3.32 $-2.59 Diluted EPS $-17.93 $-3.32 $-2.59 Revenue $ 317.38M $ 137.25M $ 103.32M Gross Profit $ $ 132.74M $ Net Income / Loss $ -391.59M $ -73.24M $ -59.42M Operating Income / Loss $ -425.15M $ -79.31M $ -67M Cost of Revenue $ 10.75M $ 4.51M $ Net Cash Flow $ -433.87M $ 83.63M $ -132.67M PE Ratio     Splits Jul 25, 2016:   1:35